NLRP3 Cancer Research Results
NLRP3, NOD-like receptor pyrin domain-containing protein 3: Click to Expand ⟱
| Source: |
| Type: |
NLRP3 (NOD-like receptor pyrin domain-containing protein 3) is a protein that plays a crucial role in the regulation of inflammation and immune responses.
NLRP3 typically has high expression in cancers, with poor prognosis.
For alzheimer's disease:
-NLRP3 is upregulated in Alzheimer's disease (AD)
-NLRP3 is activated in microglia in response to amyloid-β (Aβ) and tau aggregates.
-Promotes tau hyperphosphorylation and spread via inflammation-driven pathways.
|
Park, Parkinson's Disease (PD): Click to Expand ⟱
Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor and non-motor symptoms, and is due to the degeneration of dopaminergic neurons. It is multifactorial, caused by genetic and environmental factors and currently has no definitive cure.
-CoQ10 deficiency was observed at a higher frequency in Parkinson's disease
|
Scientific Papers found: Click to Expand⟱
| - |
Review, |
AD, |
NA |
|
|
|
- |
Review, |
Park, |
NA |
|
|
|
*neuroP↑, *antiOx↑, *ROS↓, *Inflam↓, *TNF-α↓, *IL1β↓, *PI3K↑, *Akt↑, *BBB↑, *NRF2↑, *SOD↑, *GPx↑, *MAPK↓, *Catalase↑, *HO-1↑, *COX2↓, *PGE2↓, *PPARγ↑, *TLR4↓, *GSK‐3β↓, *Aβ↓, *NLRP3↓, *BDNF↑, *TrkB↑, *GABA↑, *AChE↓, *Ach↑, *5HT↑, *cognitive↑, *MAOA↓,
| - |
Review, |
Stroke, |
NA |
|
|
|
- |
Review, |
Park, |
NA |
|
|
|
- |
Review, |
AD, |
NA |
|
|
|
*neuroP↑, *antiOx↑, *Inflam↓, *BioAv↝, *BioAv↑, *Half-Life↝, *TLR4↓, *NF-kB↓, *iNOS↓, *COX2↓, *TNF-α↓, *12LOX↓, *NLRP3↓, *ROS↓, *IL1β↓, *IL6↓, *GSK‐3β↓, *NRF2↑, *BBB↑, *SOD↑, *GPx↑, *MDA↓,
| - |
Review, |
AD, |
NA |
|
|
|
- |
Review, |
Park, |
NA |
|
|
|
*antiOx↑, *NRF2↑, *HO-1↑, *Inflam↓, *neuroP↑, *cardioP↑, *other↓, *ROS↓, *NADPH↓, *Catalase↑, *GPx1↑, *NO↓, *mt-ROS↓, *SIRT3↑, *SIRT1↑, *TLR4↓, *mTOR↓, *cognitive↑, *Sepsis↓, *PTEN↓, *Akt↓, *NLRP3↓, *AntiAg↑, *IL6↓, *TNF-α↓, *IL1β↓, *MDA↓, *memory↑, *FOXO3↑, TumCG↓, *LDL↓,
*neuroP↑, *antiOx↑, *Inflam↓, *ROS↓, *NADPH↓, *NRF2↑, *BBB↑, *IL1β↓, *IL6↓, *TNF-α↓, *NF-kB↓, *NLRP3↓, *Sepsis↓, *p‑mTOR↓, *AMPK↑, *SIRT1↑, *HO-1↑,
| - |
NA, |
AD, |
NA |
|
|
|
- |
NA, |
Park, |
NA |
|
|
|
*NLRP3↓,
| - |
Review, |
AD, |
NA |
|
|
|
- |
Review, |
Park, |
NA |
|
|
|
*NLRP3↓, *Inflam↓, *neuroP↑, *NRF2↑, *TNF-α↓, *NF-kB↓, *HO-1↑, *ROS↓,
| - |
Review, |
Var, |
NA |
|
|
|
- |
Review, |
AD, |
NA |
|
|
|
- |
Review, |
Park, |
NA |
|
|
|
*Inflam↓, *antiOx↑, *neuroP↑, *IL6↓, *IL1β↓, *NF-kB↓, *PGE2↓, *COX2↓, *MMP↑, *memory↑, *ROS↓, *Aβ↓, *HMGB1↓, TumCG↓, MARK4↓, Zeb1↓, MDM2↓, BNIP3↑, ASC↑, NLRP3↓, PI3K↓, Akt↓, Casp1↓, E-cadherin↑, STAT3↓, TLR4↓, MMP↓, ICAM-1↓, AMPK↓, IL6↑, MMP2↓, Warburg↓, Bcl-xL↓, Bcl-2↓, TumCCA↑, EMT↓, TumMeta↓, mTOR↓, HSP27↓, Casp3↑, GlucoseCon↓, lactateProd↓, VEGF↓, p‑p65↓, GIT1↓, FOXM1↓, cycD1/CCND1↓, CDK4↓, MMP9↓, HDAC2↓,
| - |
Review, |
AD, |
NA |
|
|
|
- |
Review, |
Park, |
NA |
|
|
|
- |
Review, |
Stroke, |
NA |
|
|
|
*MitoP↑, *Inflam↓, *antiOx↑, *Risk↓, *Aβ↓, *p‑tau↓, *p62↓, *PARK2↑, *MMP↑, *ROS↓, *Strength↑, *CRP↓, *IL1β↓, *IL6↓, *TNF-α↓, *AMPK↑, *NF-kB↓, *MAPK↓, *p62↑, *NRF2↑, *SOD↑, *Catalase↑, *HO-1↑, *Ferroptosis↓, *lipid-P↓, *Cartilage↑, *PI3K↓, *Akt↓, *mTOR↓, *Apoptosis↓, *neuroP↑, *Bcl-2↓, *BAX↑, *Casp3↑, *ATP↑, *eff↑, *motorD↑, *NLRP3↓, *radioP↑, *BBB↑,
| - |
Review, |
Park, |
NA |
|
|
|
- |
Review, |
AD, |
NA |
|
|
|
*Inflam↓, *antiOx↓, *neuroP↑, *p‑tau↓, *Aβ↓, *eff↑, *BioAv↓, *BioAv↑, *GSH↑, *SOD↑, *lipid-P↓, *Catalase↑, *GSR↑, *GPx↑, *ROS↓, *NRF2↑, *GutMicro↑, *Risk↓, *BBB↓, *NLRP3↓, *MAOA↓,
Showing Research Papers: 1 to 9 of 9
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 9
Pathway results for Effect on Cancer / Diseased Cells:
Mitochondria & Bioenergetics ⓘ
MMP↓, 1,
Core Metabolism/Glycolysis ⓘ
AMPK↓, 1, GlucoseCon↓, 1, lactateProd↓, 1, Warburg↓, 1,
Cell Death ⓘ
Akt↓, 1, Bcl-2↓, 1, Bcl-xL↓, 1, Casp1↓, 1, Casp3↑, 1, MDM2↓, 1,
Protein Folding & ER Stress ⓘ
HSP27↓, 1,
Autophagy & Lysosomes ⓘ
BNIP3↑, 1,
Cell Cycle & Senescence ⓘ
CDK4↓, 1, cycD1/CCND1↓, 1, TumCCA↑, 1,
Proliferation, Differentiation & Cell State ⓘ
EMT↓, 1, FOXM1↓, 1, HDAC2↓, 1, mTOR↓, 1, PI3K↓, 1, STAT3↓, 1, TumCG↓, 2,
Migration ⓘ
E-cadherin↑, 1, GIT1↓, 1, MARK4↓, 1, MMP2↓, 1, MMP9↓, 1, TumMeta↓, 1, Zeb1↓, 1,
Angiogenesis & Vasculature ⓘ
VEGF↓, 1,
Immune & Inflammatory Signaling ⓘ
ASC↑, 1, ICAM-1↓, 1, IL6↑, 1, p‑p65↓, 1, TLR4↓, 1,
Protein Aggregation ⓘ
NLRP3↓, 1,
Clinical Biomarkers ⓘ
FOXM1↓, 1, IL6↑, 1,
Total Targets: 39
Pathway results for Effect on Normal Cells:
Redox & Oxidative Stress ⓘ
antiOx↓, 1, antiOx↑, 6, Catalase↑, 4, Ferroptosis↓, 1, GPx↑, 3, GPx1↑, 1, GSH↑, 1, GSR↑, 1, HO-1↑, 5, lipid-P↓, 2, MDA↓, 2, NRF2↑, 7, PARK2↑, 1, ROS↓, 8, mt-ROS↓, 1, SIRT3↑, 1, SOD↑, 4,
Mitochondria & Bioenergetics ⓘ
ATP↑, 1, MMP↑, 2,
Core Metabolism/Glycolysis ⓘ
12LOX↓, 1, AMPK↑, 2, LDL↓, 1, NADPH↓, 2, PPARγ↑, 1, SIRT1↑, 2,
Cell Death ⓘ
Akt↓, 2, Akt↑, 1, Apoptosis↓, 1, BAX↑, 1, Bcl-2↓, 1, Casp3↑, 1, Ferroptosis↓, 1, iNOS↓, 1, MAPK↓, 2,
Transcription & Epigenetics ⓘ
Ach↑, 1, other↓, 1,
Autophagy & Lysosomes ⓘ
MitoP↑, 1, p62↓, 1, p62↑, 1,
Proliferation, Differentiation & Cell State ⓘ
FOXO3↑, 1, GSK‐3β↓, 2, mTOR↓, 2, p‑mTOR↓, 1, PI3K↓, 1, PI3K↑, 1, PTEN↓, 1,
Migration ⓘ
AntiAg↑, 1, Cartilage↑, 1,
Angiogenesis & Vasculature ⓘ
NO↓, 1,
Barriers & Transport ⓘ
BBB↓, 1, BBB↑, 4,
Immune & Inflammatory Signaling ⓘ
COX2↓, 3, CRP↓, 1, HMGB1↓, 1, IL1β↓, 6, IL6↓, 5, Inflam↓, 8, NF-kB↓, 5, PGE2↓, 2, TLR4↓, 3, TNF-α↓, 6,
Synaptic & Neurotransmission ⓘ
5HT↑, 1, AChE↓, 1, BDNF↑, 1, GABA↑, 1, MAOA↓, 2, p‑tau↓, 2, TrkB↑, 1,
Protein Aggregation ⓘ
Aβ↓, 4, NLRP3↓, 8,
Drug Metabolism & Resistance ⓘ
BioAv↓, 1, BioAv↑, 2, BioAv↝, 1, eff↑, 2, Half-Life↝, 1,
Clinical Biomarkers ⓘ
CRP↓, 1, GutMicro↑, 1, IL6↓, 5,
Functional Outcomes ⓘ
cardioP↑, 1, cognitive↑, 2, memory↑, 2, motorD↑, 1, neuroP↑, 8, radioP↑, 1, Risk↓, 2, Strength↑, 1,
Infection & Microbiome ⓘ
Sepsis↓, 2,
Total Targets: 87
Scientific Paper Hit Count for: NLRP3, NOD-like receptor pyrin domain-containing protein 3
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:75 Cells:% prod#:% Target#:908 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid
Home Page